|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| U.S. Treasury securities, at fair value | ||||||||||||||||||||
| Mortgage-backed securities, at fair value (including pledged securities of $6,474,978 and $5,879,318, respectively) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Due from counterparties | ||||||||||||||||||||
| Investment related receivable | ||||||||||||||||||||
| Derivative assets, at fair value | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Repurchase agreements | ||||||||||||||||||||
| Derivative liabilities, at fair value | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Investment related payable | ||||||||||||||||||||
| Accrued interest payable | ||||||||||||||||||||
| Collateral held payable | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Non-Related Party | ||||||||||||||||||||
| Affiliated Entity | ||||||||||||||||||||
| Total accounts payable and accrued expenses | ||||||||||||||||||||
| Due to affiliate | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred Stock, par value $0.01 per share; 50,000,000 shares authorized: 7.50% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock: 6,742,221 and 6,854,131 shares issued and outstanding, respectively ($168,556 and $171,353 aggregate liquidation preference, respectively) | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Total preferred Stock, par value $0.01 per share; 50,000,000 shares authorized: 7.50% Fixed-to-Floating Series C Cumulative Redeemable Preferred Stock: 6,742,221 and 6,854,131 shares issued and outstanding, respectively ($168,556 and $171,353 aggregate liquidation preference, respectively) | ||||||||||||||||||||
| Common Stock, par value $0.01 per share; 134,000,000 shares authorized; 102,386,106 and 71,790,532 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Retained earnings (distributions in excess of earnings) | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
| Common Stock - shares authorized (in shares) | ||||||||||||||||||||
| Common Stock, Shares, Issued | ||||||||||||||||||||
Loading...
